1 2 3
4 5 6
8 December 2016 EMA/CVMP/EWP/707299/2015 Committee for Medicinal Products for Veterinary Use (CVMP)
Concept paper for the revision of the guideline on veterinary medicinal products for fluid therapy in case of diarrhoea
7
Agreed by the CVMP’s Efficacy Working Party (EWP-V) Adopted by the Committee for Medicinal Products for Veterinary Use (CVMP) for release for consultation Start of public consultation End of consultation (deadline for comments)
September 2016 8 December 2016 16 December 2016 31 March 2017
8 9 10
The proposed guideline will replace the “Guideline on veterinary medicinal products for fluid therapy in case of diarrhoea” (NtA Volume 7, 7AE14a)
11 Comments should be provided using this template. The completed comments form should be sent to
[email protected] 12 Keywords
veterinary medicinal product, fluid therapy, rehydration, electrolyte imbalances
13 14
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.
15
1. Introduction
16
The guideline on veterinary medicinal products for fluid therapy in case of diarrhoea (7AE14a) was
17
adopted in March 1992 and has been in force since September 1992.
18
Following the review of current CVMP guidelines outlined in the ‘review and update of European
19
Medicines Agency guideline to implement best practice with regard to 3Rs (replacement, reduction and
20
refinement) in regulatory testing of medicinal products’ (EMA/CHMP/CVMP/JEG-3Rs/704685/2012), an
21
issue for review was noted in the guideline on veterinary medicinal products for fluid therapy in case of
22
diarrhoea (7AE14a; 1992) with regards to the 3Rs’ principles. Besides this issue, several other points
23
were noted.
24
2. Problem statement
25
The current guideline recommends that an untreated control group is included in clinical studies.
26
However, this may not always be possible for animal welfare reasons. Changes to the text could be
27
made to reflect this fact.
28
There have been very few applications for authorisation of new medicinal products for fluid therapy
29
indicated for diarrhoea, although dehydration can be caused by many other factors. The scope of the
30
guideline is narrow and some parts of the guideline are outdated. The guideline contains references to
31
the Directive and guidelines that have since been amended or replaced (e.g. Directive 81/852/EEC and
32
Good Clinical Practices, VICH GL 9).
33
3. Discussion (on the problem statement)
34
In the current guideline it is mentioned that for efficacy evaluation the test products could be
35
compared with a product approved in accordance with requirements of Directive 81/852/EEC. In
36
addition to this, there is a request for comparison to an untreated control group, unless justified. The
37
inclusion of a negative control is beneficial to ensure internal validity. However, this design may for
38
animal welfare reasons not be an option for severely affected animals. The text could be revised to
39
better reflect appropriate study design options taking study quality as well as animal welfare into
40
account. Furthermore, a broadening of the scope of this guideline is considered to include
41
recommendations on clinical efficacy and safety evaluation for different types of fluid therapy and for
42
different disease conditions and not only for animals suffering from diarrhoea. However, the purpose of
43
fluid therapy as stated in the guideline will remain: to correct dehydration and/or electrolyte
44
imbalances and/or metabolic imbalances and, if need be, energy losses. Such broadening of the scope
45
of the guideline may form incentives for future applications of new veterinary medicinal products.
46
4. Recommendation
47
The CVMP recommends revising the current guideline to provide more detailed and relevant
48
information regarding the selection of control groups, taking quality aspects of the study as well as
49
animal welfare into consideration. Furthermore, a broadening of the scope could be considered to
50
include recommendations on clinical efficacy and safety evaluation for different types of fluid therapy
51
and for different disease conditions.
52
5. Proposed timetable
53
8 December 2016
Concept paper adopted by CVMP for release for consultation
Concept paper for the revision of the guideline on veterinary medicinal products for fluid therapy in case of diarrhoea EMA/CVMP/EWP/707299/2015
Page 2/3
54
31 March 2017
Deadline for comments from interested parties
55
Q2-Q3 2018
Expected date for adoption of the revised guideline by EWP-V
56
Q3-Q4 2018
Expected date for adoption of the revised guideline by CVMP for release for
57
consultation
58
6. Resource requirements for preparation
59
Preparation of the revision would involve one rapporteur assisted by co-rapporteur(s).
60
Preparation of the draft guideline will require discussion at EWP-V plenary meetings, and drafting
61
group meetings (virtual), as needed.
62
7. Impact assessment (anticipated)
63
The revised guideline is not intended to increase the requirements for marketing authorisation
64
applications. The review and update of existing guideline might be more appropriate for authorization
65
of medicinal products for fluid therapy.
66
8. Interested parties
67
Veterinary pharmaceutical industry and consultants.
68
Regulatory authorities.
69
Scientific veterinary associations, e.g. FVE (Federation of Veterinarians of Europe), European College of
70
Veterinary Internal Medicine Companion Animals (ECVIM CA), European Veterinary Emergency and
71
Critical Care Society (EVECCS), European College of Equine Internal Medicine (ECEIM).
72
9. References to literature, guidelines, etc.
73
Concept paper on review and update of EMA guidelines to implement best practice with regard to 3Rs
74
(replacement, reduction and refinement) in regulatory testing of medicinal products
75
(EMA/CHMP/CVMP/JEG-3Rs/704685/2012).
Concept paper for the revision of the guideline on veterinary medicinal products for fluid therapy in case of diarrhoea EMA/CVMP/EWP/707299/2015
Page 3/3
